Benzenesulfonamides

A group of compounds that contain sulfonamide group S-linked to a benzene ring. Many benzenesulfonamide derivatives are pharmaceuticals (e.g., BOSENTAN; SULFAPYRIDINE; and SULFADIAZINE; CELECOXIB) as their sulfonamide moiety target various enzymes (e.g., CARBONIC ANHYDRASES; ACETYLCHOLINESTERASE; BUTYRYLCHOLINESTERASE; and CYCLOOXYNENASE 2).

Also Known As:

Networked: 153 relevant articles (8 outcomes, 27 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Supuran, Claudiu T: 51 articles (12/2022 - 04/2005)
2.	Nocentini, Alessio: 13 articles (01/2022 - 05/2018)
3.	Vullo, Daniela: 11 articles (12/2019 - 03/2007)
4.	Bua, Silvia: 9 articles (05/2020 - 01/2017)
5.	Carta, Fabrizio: 8 articles (12/2022 - 03/2011)
6.	Angeli, Andrea: 8 articles (01/2022 - 10/2017)
7.	Abdel-Aziz, Hatem A: 8 articles (01/2020 - 03/2013)
8.	Scozzafava, Andrea: 8 articles (01/2016 - 04/2005)
9.	Gratteri, Paola: 6 articles (01/2022 - 05/2018)
10.	Sharma, Pawan K: 5 articles (01/2022 - 03/2014)

Related Diseases

1.	Neoplasms (Cancer) 10/06/2021 - "We prepared a series of free NH and N-substituted dibenzonthiazines with potential anti-tumor activity from N-aryl-benzenesulfonamides. " 03/23/2020 - "The obtained results were analyzed in order to explain the influence of a structure of the 2-aryl-vinyl substituent and benzenesulfonamide scaffold on the anti-tumor activity. " 09/01/2018 - "Antiproliferative and Apoptotic Role of Novel Synthesized Cu(II) Complex with 3-(3-(4-fluorophenyl)Triaz-1-en-1-yl) Benzenesulfonamide in Common Cancer Models." 01/01/2017 - "Herein we describe the development of meta- or ortho-substituted fluorinated benzenesulfonamides toward the highly potent compound 10 h, which exhibits an observed dissociation constant value of 43 pm and an intrinsic dissociation constant value of 1.1 pm toward CA IX, an anticancer target that is highly overexpressed in various tumors. " 06/01/2013 - "Synthesis and biological evaluation of 4-arylphthalazones bearing benzenesulfonamide as anti-inflammatory and anti-cancer agents."
2.	Cholera 12/01/2019 - "Seeking new approach for therapeutic treatment of cholera disease via inhibition of bacterial carbonic anhydrases: experimental and theoretical studies for sixteen benzenesulfonamide derivatives."
3.	Brain Injuries (Brain Injury) 01/01/2019 - "In this study, we investigated the efficacy of 2 novel NKCC1 inhibitors, a lipophilic BMT prodrug STS5 (2-(Dimethylamino)ethyl 3-(butylamino)-4-phenoxy-5-sulfamoyl-benzoate;hydrochloride) and a novel NKCC1 inhibitor STS66 (3-(Butylamino)-2-phenoxy-5-[(2,2,2-trifluoroethylamino)methyl]benzenesulfonamide), on reducing ischemic brain injury. "
4.	Glaucoma 04/01/2005 - "These results are helpful for the design of better CA II or CA IX inhibitors based on the thioureido-benzenesulfonamide motif, with potential applications as anti-glaucoma or anti-cancer drugs." 01/01/2020 - "Discovery of Potent Dual-Tailed Benzenesulfonamide Inhibitors of Human Carbonic Anhydrases Implicated in Glaucoma and in Vivo Profiling of Their Intraocular Pressure-Lowering Action." 11/01/2019 - "Highly hydrophilic 1,3-oxazol-5-yl benzenesulfonamide inhibitors of carbonic anhydrase II for reduction of glaucoma-related intraocular pressure." 01/01/2019 - "The ureido benzenesulfonamides incorporating triazinyl moieties were investigated as inhibitors of four selected physiologically relevant human carbonic anhydrase (hCA, EC 4.2.1.1) isoforms, namely, hCA I, II, IX, and XII which are involved in various diseases such as glaucoma, epilepsy, obesity and cancer. " 12/01/2019 - "A library of twenty two novel 1,2,3-triazole benzenesulfonamides incorporating thiosemicarbazide, 5(4H)-thione-1,2,4-triazole and variously substituted phenacyl appended 1,2,4-triazole as tail were designed, synthesized and assessed for their efficacy as inhibitors against carbonic anhydrase human (h) isoforms hCA I, II, IV and IX. The physiologically important and off-target cytosolic isoform hCA I was weakly inhibited by most of the newly synthesized sulfonamides while the glaucoma associated isoform hCA II was moderately inhibited with KIs spanning in low nanomolar range (KI = 8.0 nM-0.903 μM). "
5.	Infections 01/01/2019 - "Infection of HeLa cells was significantly inhibited by the oxazole-benzenesulfonamides, and the antiviral activity was most potent against replication stages before 8 h postinfection. " 01/01/2023 - "Structure-activity-relationship (SAR) analysis revealed that although both the 3-(morpholinosulfonyl)anilino and benzenesulfonamide moieties in these compounds are critical for the potency to inhibit PRRSV infection, the morpholinosulfonyl group can be replaced by chlorine substituents without significant loss of antiviral potency. " 01/01/2019 - "These oxazole-benzenesulfonamides did not inhibit enzymatic activity of recombinant HIV-1 RT in a homopolymer assay but did inhibit reverse transcription and infection of both wild-type (WT) and nonnucleoside reverse transcriptase inhibitor (NNRTI)-resistant HIV-1 in a dose-dependent manner in HEK293T cells. " 01/01/2020 - "Benzenesulfonamide Derivatives as Calcium/Calmodulin-Dependent Protein Kinase Inhibitors and Antiviral Agents against Dengue and Zika Virus Infections."

Related Drugs and Biologics

1.	Ranitidine (Zantac)
2.	ebrotidine
3.	Carbonic Anhydrases (Carbonic Anhydrase)
4.	Prodrugs
5.	Benzoates (Benzoate)
6.	Antiviral Agents (Antivirals)
7.	diphenyl (biphenyl)
8.	ABT-737
9.	Oxazoles
10.	Metronidazole (Metric)

Related Therapies and Procedures

1.	Therapeutics